Is Dogwood Therapeutics, Inc. (DWTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 16.8% / 30% | 16.0% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 16.8% / 33% | 16.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 16.5% / 33% | 15.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 16.8% / 33% | 16.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 16.5% / 33% | 15.7% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -49.2% | |
| Return on Assets (ROA) | -19.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$9M |
| Free Cash Flow | -$9M |
| Total Debt | $16M |
| Debt-to-Equity | 0.2 |
| Current Ratio | 2.8 |
| Total Assets | $94M |
Price & Trading
| Last Close | $2.08 |
| 50-Day MA | $2.90 |
| 200-Day MA | $4.67 |
| Avg Volume | 53K |
| Beta | 2.0 |
|
52-Week Range
$1.94
| |
About Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2020 and is based in Alpharetta, Georgia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Dogwood Therapeutics, Inc. (DWTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Dogwood Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Dogwood Therapeutics, Inc.'s debt ratio?
Dogwood Therapeutics, Inc.'s debt ratio is 16.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.5%.
What are Dogwood Therapeutics, Inc.'s key financial metrics?
Dogwood Therapeutics, Inc. has a market capitalization of $66M. Return on equity stands at -49.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.